Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer

Inhibition of members of the bromodomain and extra terminal (BET) family of proteins has proven a valid strategy for cancer chemotherapy. All BET identified to date contain two bromodomains (BD; BD1 and BD2) that are necessary for recognition of acetylated lysine residues in the N-terminal regions o...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Res
Huvudupphovsmän: Slavish, P. Jake, Chi, Liying, Yun, Mi-Kyung, Tsurkan, Lyudmila, Martinez, Nancy E., Jonchere, Barbara, Chai, Sergio C., Connelly, Michele, Waddell, M. Brett, Das, Sourav, Neale, Geoffrey, Li, Zhenmei, Shadrick, William R., Olsen, Rachelle R., Freeman, Kevin W., Low, Jonathan A., Price, Jeanine E., Young, Brandon M., Bharatham, Nagakumar, Boyd, Vincent A., Yang, Jun, Lee, Richard E., Morfouace, Marie, Roussel, Martine F., Chen, Taosheng, Savic, Daniel, Guy, R. Kiplin, White, Stephen W., Shelat, Anang A., Potter, Philip M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7483993/
https://ncbi.nlm.nih.gov/pubmed/32651255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-3934
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk